For example, iron chelators such as deferoxamine (DFO) and deferiprone can inhibit the expression of IRE-regulated APP and α-syn in brain tissue, reduce the production and deposition of Aβ, and thus improve the cognitive function of patients with AD (Ma et al., 2021). Here, APP is linked to Alzheimer disease.